EMTN Supplementary Prospectus

RNS Number : 6528G

GlaxoSmithKline PLC

26 November 2020

 

Issued: 26 November 2020, London UK - LSE Announcement

Publication of Supplementary Prospectus

The following base prospectus dated 26 November 2020 has been approved by the UK Listing Authority and is available for viewing:

GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GSK Capital K.K. £20,000,000,000 Euro Medium Term Note Programme

Copies of the supplementary prospectus have been submitted to the UK Listing Authority's National Storage Mechanism submission portal via the Electronic Submission System.  The base prospectus will shortly be available for inspection at and can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

For further information, please contact:

GlaxoSmithKline plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

Enquiries:

UK Media enquiries:	David Mawdsley Simon Steel	[phone] [phone]
European Analyst/Investor enquiries:	James Dodwell Danielle Smith	[phone] [phone]

BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENTARY PROSPECTUS

Please note that the information contained in the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base p rospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above

GlaxoSmithKline plc Registered in England & Wales: No. 3888792

Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS

 

END

 

 

PSPEAAFKADFEFFA